应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
01548 金斯瑞生物科技
未开盘 09-28 16:08:28
42.000
-0.940
-2.19%
最高
42.900
最低
40.800
成交量
2,910万
今开
42.900
昨收
42.940
日振幅
4.89%
总市值
957.60亿
流通市值
957.60亿
总股本
22.80亿
成交额
12.14亿
换手率
1.28%
流通股本
22.80亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
异动解读｜金斯瑞生物科技盘中下跌3.12%，连续大涨后再度遭遇获利回吐
行情直击 · 09-28 09:37
异动解读｜金斯瑞生物科技盘中下跌3.12%，连续大涨后再度遭遇获利回吐
港股全天缩量调整 恒指收盘跌超1% 创新药板块逆势走强
每日经济新闻 · 09-25
港股全天缩量调整 恒指收盘跌超1% 创新药板块逆势走强
港股生物医药概念股走高，金斯瑞生物科技涨超9%
每日经济新闻 · 09-25
港股生物医药概念股走高，金斯瑞生物科技涨超9%
港股异动 | 金斯瑞生物科技早盘涨超7% 金斯瑞与礼来TuneLab合作 强化公司AI药物发现生态
智通财经 · 09-25
港股异动 | 金斯瑞生物科技早盘涨超7% 金斯瑞与礼来TuneLab合作 强化公司AI药物发现生态
金斯瑞生物科技盘中涨逾8% 光大证券维持“买入”评级
新浪港股 · 09-25
金斯瑞生物科技盘中涨逾8% 光大证券维持“买入”评级
港股异动 | 金斯瑞生物科技(01548.HK)早盘涨超7% 金斯瑞与礼来TuneLab合作 强化公司AI药物发现生态
智通财经 · 09-25
港股异动 | 金斯瑞生物科技(01548.HK)早盘涨超7% 金斯瑞与礼来TuneLab合作 强化公司AI药物发现生态
AI医疗概念股盘初多股扬升 金斯瑞生物科技（01548）领涨7.05%
金吾财讯 · 09-25
AI医疗概念股盘初多股扬升 金斯瑞生物科技（01548）领涨7.05%
异动解读｜金斯瑞生物科技盘中上涨8.05%，前日获利回吐后资金回补叠加AI制药催化持续
行情直击 · 09-25
异动解读｜金斯瑞生物科技盘中上涨8.05%，前日获利回吐后资金回补叠加AI制药催化持续
生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖
金吾财讯 · 09-24
生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖
异动解读｜金斯瑞生物科技盘中下跌3.45%，连续大涨后获利回吐叠加板块整体走弱
行情直击 · 09-24
异动解读｜金斯瑞生物科技盘中下跌3.45%，连续大涨后获利回吐叠加板块整体走弱
CRO概念股早盘多数走高 金斯瑞生物科技及昭衍新药均涨超4%
新浪港股 · 09-23
CRO概念股早盘多数走高 金斯瑞生物科技及昭衍新药均涨超4%
异动解读｜金斯瑞生物科技盘中上涨3.11%，AI制药利好持续共振叠加降低交易门槛
行情直击 · 09-23
异动解读｜金斯瑞生物科技盘中上涨3.11%，AI制药利好持续共振叠加降低交易门槛
金斯瑞生物科技（01548）宣布2026年10月起每手买卖单位缩减至1,000股
公告速递 · 09-21
金斯瑞生物科技（01548）宣布2026年10月起每手买卖单位缩减至1,000股
金斯瑞生物科技(01548.HK)每手买卖单位将更改为1000股
智通财经 · 09-21
金斯瑞生物科技(01548.HK)每手买卖单位将更改为1000股
【券商聚焦】光大证券维持金斯瑞生物科技（01548）买入评级 指AI驱动订单高增
金吾财讯 · 09-21
【券商聚焦】光大证券维持金斯瑞生物科技（01548）买入评级 指AI驱动订单高增
金斯瑞生物科技盘中涨超7% 小摩维持“增持”评级
新浪港股 · 09-21
金斯瑞生物科技盘中涨超7% 小摩维持“增持”评级
港股生物医药股全线大涨，金斯瑞涨超6%，药明康德涨超3%
老虎快讯 · 09-21
港股生物医药股全线大涨，金斯瑞涨超6%，药明康德涨超3%
医药外包概念盘初走高 昭衍新药（06127）涨6.14% 机构指CXO为医药行业中最亮眼板块之一
金吾财讯 · 09-21
医药外包概念盘初走高 昭衍新药（06127）涨6.14% 机构指CXO为医药行业中最亮眼板块之一
港股异动 | 金斯瑞生物科技(01548)早盘涨超7% 大模型厂商下场AI制药 机构指公司商业模型发生深刻变化
智通财经 · 09-21
港股异动 | 金斯瑞生物科技(01548)早盘涨超7% 大模型厂商下场AI制药 机构指公司商业模型发生深刻变化
生物医药板块盘初普升 复宏汉霖（02696）涨7.96% 机构指中国创新药进入全球价值兑现阶段
金吾财讯 · 09-21
生物医药板块盘初普升 复宏汉霖（02696）涨7.96% 机构指中国创新药进入全球价值兑现阶段
加载更多
公司概况
公司名称：
金斯瑞生物科技
所属市场：
SEHK
上市日期：
--
主营业务：
金斯瑞生物科技股份有限公司是一家主要从事生产及销售生命科学研究产品及服务的投资控股公司。该公司通过五个分部开展业务。生命科学服务及产品分部提供全面的研究服务及产品。生物制剂开发服务分部以一个综合平台提供全面服务，旨在帮助生物制药及生物技术公司加快治疗性抗体及基因、细胞疗法产品的开发。工业合成生物产品分部通过使用基因工程建构非病源微生物株，提供工业酶开发和生产。细胞疗法分部发现和开发用于治疗液体及固体肿瘤的CAR-T疗法。经营管理分部主要为其他分部提供共享服务。该公司主要在中国国内和海外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"01548","market":"HK","secType":"STK","nameCN":"金斯瑞生物科技","latestPrice":42,"timestamp":1790582908004,"preClose":42.94,"halted":0,"volume":29102166,"delay":0,"changeRate":-0.02189101071262221,"floatShares":2280000000,"shares":2280000000,"eps":-1.9282968541617636,"marketStatus":"未开盘","change":-0.94,"latestTime":"09-28 16:08:28","open":42.9,"high":42.9,"low":40.8,"amount":1214177449,"amplitude":0.048905,"askPrice":42,"askSize":10000,"bidPrice":41.98,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-2.289589707382129,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790645400000},"marketStatusCode":0,"adr":0,"listingDate":1451404800000,"exchange":"SEHK","adjPreClose":42.94,"openAndCloseTimeList":[[1790559000000,1790568000000],[1790571600000,1790582400000]],"volumeRatio":0.8019989883031531,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01548","defaultTab":"news","newsList":[{"id":"1193376572","title":"异动解读｜金斯瑞生物科技盘中下跌3.12%，连续大涨后再度遭遇获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1193376572","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193376572?lang=zh_cn&edition=full","pubTime":"2026-09-28 09:37","pubTimestamp":1790559433,"startTime":"0","endTime":"0","summary":"9月28日，金斯瑞生物科技盘中下跌3.12%，报41.2港元，成交额9037.84万港元。当前股价已显著超过摩根大通此前给出的41港元目标价，短期获利盘压力加大。值得注意的是，摩根大通此前曾场外减持公司约3375万股、涉资约11.05亿港元，好仓比例由7.37%降至5.64%，机构层面已有阶段性兑现动作，今日走势与9月24日获利回吐格局类似。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"金斯瑞生物科技回调，机构减持压力显现","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670441122","title":"港股全天缩量调整 恒指收盘跌超1% 创新药板块逆势走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2670441122","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670441122?lang=zh_cn&edition=full","pubTime":"2026-09-25 17:42","pubTimestamp":1790329328,"startTime":"0","endTime":"0","summary":"今日（9月25日），因中秋节假期，港股通渠道全天关闭，港股市场缩量调整，全天仅成交1022亿港元。恒生指数早盘一度跌近2%，午后跌幅收窄，最终收盘报24510.09点，下跌251.05点，跌幅1.01%。恒生科技指数早盘一度跌超2.6%，最终收盘报4311.78点，下跌49.35点，跌幅1.13%。热点板块方面，创新药板块逆势走强。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609253884301978.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609253884301978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1576","03419","03115","HK0000306685.HKD","07500","HK0000306701.USD","BK1141","07200","MHImain","09115","513600","02833","HSI","01548","HSTECH","MCHmain","03037","02800","HHImain","83115","BK1583","82800","HK0000320223.HKD","HK0000320264.USD","07300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670544393","title":"港股生物医药概念股走高，金斯瑞生物科技涨超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670544393","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670544393?lang=zh_cn&edition=full","pubTime":"2026-09-25 14:23","pubTimestamp":1790317403,"startTime":"0","endTime":"0","summary":"港股生物医药概念股走高，金斯瑞生物科技涨超9%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609253884270486.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609253884270486.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","HK0000306701.USD","KCAI","01548","161726","399441","VXUS","XBI","BK1583","BK1141","HK0000320264.USD","BK4588","HK0000320223.HKD","BK1576","BK4581","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670441453","title":"港股异动 | 金斯瑞生物科技早盘涨超7% 金斯瑞与礼来TuneLab合作 强化公司AI药物发现生态","url":"https://stock-news.laohu8.com/highlight/detail?id=2670441453","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670441453?lang=zh_cn&edition=full","pubTime":"2026-09-25 11:36","pubTimestamp":1790307411,"startTime":"0","endTime":"0","summary":"9月25日，$金斯瑞生物科技$早盘涨超7%。消息面上，金斯瑞近日宣布，与礼来的AIDD协作平台Lilly TuneLab达成合作。公司将向TuneLab参与企业提供湿实验服务，助力其快速生成实验数据，将AI预测转化为生物学验证数据，加速候选药物评估。摩根大通最新研报表示，礼来TuneLab选择金斯瑞作为三家核心湿实验室合作伙伴之一，意义不只是单笔CRO订单，而是进入100多家Biotech客户生态、打通干湿实验闭环的战略入口。","market":"hk","thumbnail":"https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3c6daacf13f78492ec38a4e178ddca49"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500859.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670041495","title":"金斯瑞生物科技盘中涨逾8% 光大证券维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2670041495","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670041495?lang=zh_cn&edition=full","pubTime":"2026-09-25 10:14","pubTimestamp":1790302440,"startTime":"0","endTime":"0","summary":"模拟交易客户端金斯瑞生物科技盘中涨超8%。截至发稿，股价上涨5.84%，现报42.86港元，成交额2.214亿港元。金斯瑞近日宣布，与礼来的AIDD协作平台Lilly TuneLab达成合作。光大证券指出，随着大模型厂商下场AI制药，公司的商业模型已发生深刻变化。盈利预测方面，考虑AI制药行业变化带来需求增量，光大证券上调26年归母净利润预测为0.66亿美元，维持27年预测为2.70亿美元，新增28年预测为3.72亿美元，对应EPS分别为0.03/0.12/0.16美元，维持“买入”评级。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-25/doc-inisyywf7885292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["601788","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670531414","title":"港股异动 | 金斯瑞生物科技(01548.HK)早盘涨超7% 金斯瑞与礼来TuneLab合作 强化公司AI药物发现生态","url":"https://stock-news.laohu8.com/highlight/detail?id=2670531414","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670531414?lang=zh_cn&edition=full","pubTime":"2026-09-25 10:06","pubTimestamp":1790302007,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1141","BK1576","BK1583","HK0000320223.HKD","HK0000306685.HKD","01548","HK0000306701.USD","HK0000320264.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670148064","title":"AI医疗概念股盘初多股扬升 金斯瑞生物科技（01548）领涨7.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670148064","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670148064?lang=zh_cn&edition=full","pubTime":"2026-09-25 09:46","pubTimestamp":1790300777,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股AI医疗概念股盘初多股扬升，截至发稿，金斯瑞生物科技 涨7.05%，轻松健康涨1.53%，药明康德涨1.17%，药明生物涨1.16%，云顶新耀涨0.65%。另一消息面上，西南证券发布研报称，AI制药行业已历经萌芽期、发展期，自2024年起进入成熟深化的商业化验证阶段，竞争核心由模型算法转向高质量数据、实验闭环能力以及AI药物商业化兑现能力。基于AI制药处于商业化价值验证关键期，该机构建议从研发、商业化、BD三大维度把握投资机会。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992478","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320764599.SGD","LU0516422952.EUR","LU0181495838.USD","LU0823426480.USD","CHAT","LU2039709279.SGD","AIPO","01952","ARTY","LU0348825331.USD","LU0359202008.SGD","HK0000320223.HKD","BK1576","LU1046422090.SGD","159891","HK0000306701.USD","LU0029874061.USD","LU0516423091.SGD","QTOC","LU0029874905.USD","LU0417516738.SGD","02269","01548","LU0043850808.USD","LU1880383366.USD","BK1589","SG9999002463.SGD","LU0348827113.USD","LU0634319403.HKD","LU0051755006.USD","02359","AGIX","02661","LU0327786744.USD","KURE","HK0000306685.HKD","VTHR","LU0052750758.USD","BK1141","LU0708995583.HKD","LU0456827905.SGD","LU0516423174.USD","LU1242518931.SGD","LU2125910500.SGD","LU2242644610.SGD","LU0359201612.USD","BK1583","LU0588546209.SGD","LU0307460666.USD","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168872438","title":"异动解读｜金斯瑞生物科技盘中上涨8.05%，前日获利回吐后资金回补叠加AI制药催化持续","url":"https://stock-news.laohu8.com/highlight/detail?id=1168872438","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168872438?lang=zh_cn&edition=full","pubTime":"2026-09-25 09:31","pubTimestamp":1790299903,"startTime":"0","endTime":"0","summary":"9月25日，金斯瑞生物科技盘中上涨8.05%，报42.6港元，成交额7126.76万港元。消息面上，公司近期与礼来旗下AI药物发现平台Lilly TuneLab达成合作，将提供湿实验室服务加速AI预测向生物学验证数据转化，光大证券指出AI驱动蛋白订单预计下半年保持三位数百分比增长。此外，Anthropic近日披露Claude大模型在科学研究中实现新突破，\"干湿实验闭环\"逻辑持续强化，叠加医药工业\"十五五\"规划明确支持AI赋能药物研发，多重催化共振推动资金回补。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"金斯瑞生物科技大涨，AI制药催化持续","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451177","title":"生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451177","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669451177?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:36","pubTimestamp":1790228201,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块午后全线走低，截至发稿，诺诚健华 跌10.48%，荣昌生物跌7.99%，复宏汉霖跌7.68%，康诺亚-B跌5.86%，再鼎医药跌5.32%，君实生物跌4.53%，金斯瑞生物科技跌4.21%，康方生物跌3.54%，科伦博泰生物跌3.11%，泰格医药跌2.35%，药明生物跌1.80%，百济神州跌1.56%，药明合联跌1.12%。消息面上，国盛证券发布研报称，医药行业需求尚未明显回暖，降本增效、费用精细化管理已成为利润端的重要支撑。下半年关注流感旺季带来的阶段性需求催化。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992441","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","LU3063872942.SGD","BK1583","LU0561508036.HKD","399441","LU0516423174.USD","LU0540923850.HKD","LU0516422366.SGD","BK1515","01877","LU1770034418.SGD","LU1303224171.USD","LU0140636845.USD","161726","02696","03347","BK1141","LU0348783233.USD","06990","LU1242518931.SGD","LU1719994722.HKD","09688","09926","688428","LU1880383366.USD","09969","LU0828237510.HKD","SG9999002463.SGD","KURE","SG9999002562.SGD","LU2399975544.HKD","01548","02268","06160","LU0856984785.SGD","XBI","BK1576","LU1961090484.USD","SG9999014674.SGD","LU1242518857.USD","LU0456846285.SGD","LU0348825331.USD","LU2039709279.SGD","02162","BK4581","LU2328871848.SGD","02269","09995","LU0348766576.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169144901","title":"异动解读｜金斯瑞生物科技盘中下跌3.45%，连续大涨后获利回吐叠加板块整体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1169144901","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169144901?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:03","pubTimestamp":1790226235,"startTime":"0","endTime":"0","summary":"9月24日，金斯瑞生物科技盘中下跌3.45%，报40.32港元，成交额6.48亿港元。此前该股因与礼来TuneLab达成AI制药合作、CXO板块高景气等多重利好连续走强，近一周内股价自约32港元一路攀升至盘中高点43.12港元，已显著超过摩根大通此前给出的41港元目标价，短期获利盘压力加大。值得关注的是，摩根大通此前在9月15日曾场外减持公司约3375万股，涉资约11.05亿港元，好仓比例由7.37%降至5.64%，显示机构层面已有阶段性兑现动作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"金斯瑞生物科技回落，获利回吐压力显现","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669174258","title":"CRO概念股早盘多数走高 金斯瑞生物科技及昭衍新药均涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669174258","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669174258?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:40","pubTimestamp":1790134800,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端CRO概念股早盘多数走高，截至发稿，金斯瑞生物科技（01548）上涨4.70%，报42.36港元；昭衍新药（06127）上涨4.45%，报27.70港元；康龙化成（03759）上涨2.51%，报31.02港元；泰格医药（03347）上涨0.82%，报46.96港元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-23/doc-inisusyi5326555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","603127","HK0000306701.USD","BK1141","HK0000320264.USD","BK0216","06127","01548","BK1576","HK0000306685.HKD","HK0000320223.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159050407","title":"异动解读｜金斯瑞生物科技盘中上涨3.11%，AI制药利好持续共振叠加降低交易门槛","url":"https://stock-news.laohu8.com/highlight/detail?id=1159050407","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159050407?lang=zh_cn&edition=full","pubTime":"2026-09-23 10:22","pubTimestamp":1790130167,"startTime":"0","endTime":"0","summary":"9月23日，金斯瑞生物科技盘中上涨3.11%，报41.76港元，成交额3.79亿港元，延续近期强势表现。消息面上，公司近期与礼来旗下AI药物发现协作平台Lilly TuneLab达成合作，将为参与企业提供湿实验服务，加速AI预测向生物学验证数据转化。光大证券指出，公司商业模型已发生深刻变化，AI驱动蛋白订单预计下半年及之后保持三位数百分比增长。此外，公司此前完成约23.27亿港元配售，约70%净募资将用于扩大AIDD平台产能及基础设施。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"金斯瑞生物科技上涨，AI制药利好持续发酵","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128048508","title":"金斯瑞生物科技（01548）宣布2026年10月起每手买卖单位缩减至1,000股","url":"https://stock-news.laohu8.com/highlight/detail?id=1128048508","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128048508?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:35","pubTimestamp":1789983341,"startTime":"0","endTime":"0","summary":"金斯瑞生物科技股份有限公司9月21日公告称，公司在香港联合交易所主板买卖的已发行普通股股份之每手买卖单位将自2026年10月14日9时正起，由现行的2,000股调整为1,000股。董事会表示，此举旨在直接将每手买卖单位市值减半，从而降低股份交易的最低门槛。以公告当日每股收市价41.40港元测算，现行每手2,000股的市值约为82,800港元；调整后，每手1,000股的市值约为41,400港元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669154876","title":"金斯瑞生物科技(01548.HK)每手买卖单位将更改为1000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669154876","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669154876?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:30","pubTimestamp":1789983010,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HK0000306701.USD","BK1576","HK0000320223.HKD","BK1141","HK0000306685.HKD","HK0000320264.USD","BK1583","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669137288","title":"【券商聚焦】光大证券维持金斯瑞生物科技（01548）买入评级 指AI驱动订单高增","url":"https://stock-news.laohu8.com/highlight/detail?id=2669137288","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669137288?lang=zh_cn&edition=full","pubTime":"2026-09-21 13:41","pubTimestamp":1789969309,"startTime":"0","endTime":"0","summary":"公司近期完成总额约23.3亿港元的港股配售，其中约70%净募资拟用于扩大AIDD平台产能和基础设施。基于客户需求，公司预计AI驱动蛋白订单预期26年下半年及之后保持3位数百分比增长。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992077","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AIPO","QTOC","VTHR","601788","CHAT","ARTY","KCE","AGIX","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669399351","title":"金斯瑞生物科技盘中涨超7% 小摩维持“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669399351","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669399351?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:19","pubTimestamp":1789957140,"startTime":"0","endTime":"0","summary":"模拟交易客户端金斯瑞生物科技盘中涨超7%。截至发稿，股价上涨5.34%，现报41.44港元，成交额9.77亿港元。金斯瑞近日宣布，与礼来的AIDD协作平台Lilly TuneLab达成合作。摩根大通发布研报称，礼来宣布与金斯瑞生物科技等达成TuneLab合作协议，该行维持金斯瑞“增持”评级及目标价41港元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-21/doc-inispynh6014007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153938851","title":"港股生物医药股全线大涨，金斯瑞涨超6%，药明康德涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1153938851","media":"老虎快讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153938851?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:14","pubTimestamp":1789956879,"startTime":"0","endTime":"0","summary":"港股市场生物医药股全线大涨，其中，复宏汉霖涨超10%，君实生物、康方生物涨超8%，康诺亚-B、诺诚健华涨超7%，荣昌生物、金斯瑞生物科技、药明生物、科伦博泰生物涨超6%，药明康德、泰格医药、药明合联涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548","09926","02268","02269","06990","09969","09995","03347","01877","02162","02359","02696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139506","title":"医药外包概念盘初走高 昭衍新药（06127）涨6.14% 机构指CXO为医药行业中最亮眼板块之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139506","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139506?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:10","pubTimestamp":1789956632,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药外包概念盘初走高，截至发稿，昭衍新药（06127）涨6.14%，药明生物（02269）涨4.97%，金斯瑞生物科技（01548）涨4.47%，维亚生物（01873）涨3.75%，药明康德（02359）涨3.40%，泰格医药（03347）涨2.52%，康龙化成（03759）涨2.64%。中邮证券研究指，2026中报看，CXO行业是医药行业中最亮眼板块之一。数据上看，CDMO龙头、安评及临床CRO是三条景气主线。估值上看，CDMO龙头公司按2027PE仍处于合理区间，CRO环节公司报表仍处修复阶段，新签高毛利订单待转化，因此表观估值较高，但预计随着订单的逐渐周转快速消化。","market":"other","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992050","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1794554557.SGD","LU0348766576.USD","LU2242644610.SGD","BK1589","LU1242518857.USD","BK1141","LU3063872942.SGD","LU1880383366.USD","LU0348825331.USD","LU0516423091.SGD","LU2125910500.SGD","02269","01548","HK0000320223.HKD","02359","BK1515","KURE","BK1610","LU0307460666.USD","LU0359201612.USD","LU0588546209.SGD","LU0456846285.SGD","603127","LU0516422366.SGD","LU0516422440.USD","159938","LU0516422952.EUR","09939","SG9999002463.SGD","HK0000306701.USD","LU0181495838.USD","CXO","03759","LU0029874905.USD","03347","LU0051755006.USD","LU0052750758.USD","BK1583","LU0320764599.SGD","LU0561508036.HKD","06127","LU0516423174.USD","WX","01873","LU0029874061.USD","LU0359202008.SGD","LU0540923850.HKD","BK1161","LU0039217434.USD","LU0043850808.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139317","title":"港股异动 | 金斯瑞生物科技(01548)早盘涨超7% 大模型厂商下场AI制药 机构指公司商业模型发生深刻变化","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139317","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139317?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:04","pubTimestamp":1789956243,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，金斯瑞生物科技早盘涨超7%。截至发稿，涨6.56%，报41.92港元，成交额8.01亿港元。消息面上，金斯瑞近日宣布，与礼来的AIDD协作平台Lilly TuneLab达成合作。公司将向TuneLab参与企业提供湿实验服务，助力其快速生成实验数据，将AI预测转化为生物学验证数据，加速候选药物评估。光大证券指出，随着大模型厂商下场AI制药，公司的商业模型已发生深刻变化。基于客户需求，公司预计AI驱动蛋白订单预期26年下半年及之后保持3位数百分比增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["QTOC","HK0000320264.USD","HK0000306685.HKD","BK4588","BK4585","BK1576","EPAI","BK1191","HK0000320223.HKD","GPTZ","BK1141","CHAT","01548","BK1583","WISE","ARTY","01477","HK0000306701.USD","KCAI","AGIX","BK1574","AIPO","LRNZ","VXUS","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669136031","title":"生物医药板块盘初普升 复宏汉霖（02696）涨7.96% 机构指中国创新药进入全球价值兑现阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2669136031","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669136031?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:49","pubTimestamp":1789955355,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块盘初普升，截至发稿，复宏汉霖 涨7.96%，诺诚健华涨7.34%，荣昌生物涨6.69%，康诺亚-B涨6.52%，康方生物涨6.46%，君实生物涨6.41%，金斯瑞生物科技涨5.80%，科伦博泰生物涨5.63%，药明生物涨4.47%，药明康德涨2.90%，泰格医药涨2.69%，百济神州涨2.07%，药明合联涨1.75%。中信证券表示，中国创新药进入全球价值兑现阶段，头部国际化创新药企业有望迎来产品全球价值兑现期。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/OTZhY2RjY2M0NGRhYmE3MDgxYTI5ZDA4OTNlODY4MjM3MDk5ODc3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992049","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06990","BK1610","LU0320764243.SGD","BK1588","LU0244354667.USD","LU0463099449.HKD","LU0029874905.USD","LU2476274720.SGD","BK4588","03347","LU0052750758.USD","BK1515","LU1188198961.HKD","09995","LU0326950275.SGD","LU0348784397.USD","399441","LU0540923850.HKD","LU0561508036.HKD","LU0979878070.USD","XBI","HK0000165453.HKD","LU1303224171.USD","01877","02696","02162","LU2488822045.USD","02268","LU0456827905.SGD","LU1961090484.USD","KURE","LU0320764599.SGD","LU0327786744.USD","LU0516422952.EUR","LU0348767384.USD","LU0196878994.USD","LU0348766576.USD","01548","LU1880383366.USD","06160","02359","02269","09926","161726","LU2242644610.SGD","LU0634319403.HKD","LU2045819591.USD","09969","LU0128522744.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genscript.com","stockEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.1993},{"period":"3month","weight":2.4342},{"period":"6month","weight":2.5443},{"period":"1year","weight":1.6786},{"period":"ytd","weight":2.3816}],"compareEarnings":[{"period":"1week","weight":-0.016},{"period":"1month","weight":-0.0368},{"period":"3month","weight":0.077},{"period":"6month","weight":-0.0258},{"period":"1year","weight":-0.0569},{"period":"ytd","weight":-0.0385}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"金斯瑞生物科技股份有限公司是一家主要从事生产及销售生命科学研究产品及服务的投资控股公司。该公司通过五个分部开展业务。生命科学服务及产品分部提供全面的研究服务及产品。生物制剂开发服务分部以一个综合平台提供全面服务，旨在帮助生物制药及生物技术公司加快治疗性抗体及基因、细胞疗法产品的开发。工业合成生物产品分部通过使用基因工程建构非病源微生物株，提供工业酶开发和生产。细胞疗法分部发现和开发用于治疗液体及固体肿瘤的CAR-T疗法。经营管理分部主要为其他分部提供共享服务。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.000341},{"month":2,"riseRate":0.545455,"avgChangeRate":0.075475},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.060575},{"month":4,"riseRate":0.545455,"avgChangeRate":0.057883},{"month":5,"riseRate":0.454545,"avgChangeRate":0.061694},{"month":6,"riseRate":0.545455,"avgChangeRate":0.030877},{"month":7,"riseRate":0.636364,"avgChangeRate":0.112261},{"month":8,"riseRate":0.454545,"avgChangeRate":0.171691},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.043609},{"month":10,"riseRate":0.6,"avgChangeRate":0.095918},{"month":11,"riseRate":0.6,"avgChangeRate":0.045101},{"month":12,"riseRate":0.3,"avgChangeRate":0.042047}],"exchange":"SEHK","name":"金斯瑞生物科技","nameEN":"GENSCRIPT BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金斯瑞生物科技,01548,金斯瑞生物科技股票,金斯瑞生物科技股票老虎,金斯瑞生物科技股票老虎国际,金斯瑞生物科技行情,金斯瑞生物科技股票行情,金斯瑞生物科技股价,金斯瑞生物科技股市,金斯瑞生物科技股票价格,金斯瑞生物科技股票交易,金斯瑞生物科技股票购买,金斯瑞生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金斯瑞生物科技(01548)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金斯瑞生物科技(01548)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}